Compare Repligen Corporation Common Stock (RGEN) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while iShares 10 20 Year Treasury Bond ETF trades at $93.76 (market cap $11.47B). The key difference: Repligen Corporation Common Stock and iShares 10 20 Year Treasury Bond ETF are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and iShares 10 20 Year Treasury Bond ETF for 62 Days on average.
| RGEN | TLH | |
|---|---|---|
Market Cap | $11.14B | $11.47B |
Volume | 1,259,263 | 2,063,925 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $105.36 |
52-Week Low | $102.87 | $91.34 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $92.56 with a slight 0.34% daily gain amid a challenging bond market environment. Technical indicators signal a bearish trend with selling pressure outweighing buying signals. Recent trading volume spikes indicate heightened investor interest as Treasury yields reach multi-decade highs, creating volatility for long-duration bond ETFs.
The outlook remains cautious as rising interest rates pressure bond prices, though the ETF provides exposure to US Treasury securities. Key risks include continued Fed tightening and inflation concerns, while potential stabilization in yields could offer support. Institutional activity shows mixed positioning with some funds reducing exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
